glp-1 receptor agonists GLP-1 receptor agonists and DPP-4

Human efficacy is unproven

Neurological and anti-inflammatory effects: Shows promise in Alzheimers disease and neuroprotection

They do not deliver overnight results, but consistent use produces real structural change

Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes of administration TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and tissue binding characteristics Combined formulation provides both immediate and sustained bioactivity Distribution studies suggest that while each peptide follows distinct pathways, injury sites tend to concentrate all three components, potentially enhancing local therapeutic effects through multiple mechanisms